- Therapeutic areas in focus Volume 73 Summer 2022
Breathing new life into respiratory research
COVID-19 has accelerated innovation and growth in the respiratory field, but in what ways?Obstacles in oncology
Pharma needs to work in collaboration with the government in order to address the growing cancer patient burdenRethinking pain management in 2022
How can patients be better supported to manage their debilitating chronic pain?In affiliation with Pharmafocus Contents
Therapeutic Areas in FocusVOLUME 73 SUMMER 2022The COVID-19 pandemic has brought with it a barrage of challenges for cancer patients and NHS staff alike. The increased waiting times and pressure across the healthcare system has meant that treatment for cancer patients has been affected due to delayed diagnoses,
cancelled or postponed appointments, and concerns about coming into hospital. This section explores how pharma can work collaboratively with the NHS to address these challenges within the field of oncology.COVID-19 illuminated the need for safe treatments that manage the inflammatory responses to respiratory diseases, and opened the door for potential new treatments. In this section, health experts explore how technology can improve the way clinical trials in respiratory are run, and remark on the ongoing need for effective, safe, and well tolerated medicines for conditions such as COPD and idiopathic pulmonary fibrosis.With a significant need to deliver quick, effective pain management to patients facing chronic or cancer-related pain, healthcare professionals are also under pressure to provide options with the lowest side-effect profiles possible. Exciting pathways for this include pain relief via transdermal delivery, CBD therapies, and compounded medicines, to deliver tailor-made treatments to patients, at the site of pain.Many patients of rare diseases are neglected in research, with only one in 20 rare diseases having treatment options, creating a significant cumulative effect. Where the pandemic has made it harder for rare disease patients to receive treatment and participate in innovative research, significant ground is being made in the fields of gene editing, combination treatments, and viral delivery strategies.Executive Director – PMGroup Worldwide Ltd - Karl Equi kequi@pmlive.comEditorial Coordinator - Will Brown will@samedanltd.comJournalist & Editorial Assistant - Lina Adams lina@pharmafile.comJournalist & Editorial Assistant - Ana Ovey ana@pharmafile.comSales Manager - Eliot Haynes eliot@pharmafile.comDesigner - Peter May designer@samedanltd.comPharmafile is published each Spring and Autumn.
For subscription information, please contact us.
The opinions and views expressed by contributors in this book are not necessarily those of the Publisher and, while every care has been taken in the preparation of this book, the Publisher is not responsible for such opinion and views, or for any inaccuracies in the contributions and data it contains.
The Publisher is not responsible for any images or graphics supplied by contributors. The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means, without prior permission from Samedan Ltd.
ISSN 0959-8758. All rights reserved. © 2021 Samedan Ltd Cover image: © Unsplash | CDCContact us:Pharmafile, Samedan Ltd, Suite E, 11 BellYard Mews, 175 Bermondsey Street, London SE1 3TN, United KingdomT: +44 (0)20 7724 3456
www.pharmafile.com
